ALT5 Sigma Corporation Announces Record Date for Alyea Therapeutics Corporation Transaction
ALT5 Sigma Corporation (NASDAQ:ALTS) has announced June 2, 2025, as the record date for its planned separation of healthcare assets under Alyea Therapeutics Corporation. The company aims to split its healthcare and fintech segments to allow each entity to focus on their respective business needs. The specific details of the transaction, whether it will be structured as a split-off, spin-off, or another related transaction, will be announced later in 2025.
All equity holders and holders of equity-underlying securities as of the record date will be eligible to participate in the Alyea distribution. Currently, no shareholder vote is required, though the company will notify stakeholders if voting becomes necessary for the distribution.
ALT5 Sigma Corporation (NASDAQ:ALTS) ha annunciato il 2 giugno 2025 come data di riferimento per la prevista separazione delle attività sanitarie sotto Alyea Therapeutics Corporation. L'azienda intende dividere i segmenti healthcare e fintech per permettere a ciascuna entità di concentrarsi sulle proprie esigenze di business. I dettagli specifici della transazione, che potrà essere strutturata come split-off, spin-off o altra operazione correlata, saranno comunicati più avanti nel 2025.
Tutti i titolari di azioni e di strumenti finanziari sottostanti azioni alla data di riferimento avranno diritto a partecipare alla distribuzione Alyea. Al momento, non è richiesto alcun voto da parte degli azionisti, ma la società informerà gli stakeholder qualora fosse necessario un voto per la distribuzione.
ALT5 Sigma Corporation (NASDAQ:ALTS) ha anunciado el 2 de junio de 2025 como la fecha de registro para la separación planificada de sus activos de salud bajo Alyea Therapeutics Corporation. La compañía busca dividir sus segmentos de salud y fintech para que cada entidad pueda enfocarse en sus respectivas necesidades comerciales. Los detalles específicos de la transacción, ya sea que se estructure como un split-off, spin-off u otra operación relacionada, se anunciarán más adelante en 2025.
Todos los titulares de acciones y de valores subyacentes a acciones en la fecha de registro serán elegibles para participar en la distribución de Alyea. Actualmente, no se requiere voto de los accionistas, aunque la empresa notificará a las partes interesadas si es necesario un voto para la distribución.
ALT5 Sigma Corporation (NASDAQ:ALTS)는 2025년 6월 2일을 Alyea Therapeutics Corporation 산하 의료 자산 분리 계획의 기준일로 발표했습니다. 회사는 헬스케어 부문과 핀테크 부문을 분리하여 각 사업부가 자체 비즈니스 요구에 집중할 수 있도록 할 예정입니다. 분리 방식이 스플릿오프, 스핀오프 또는 기타 관련 거래가 될지에 대한 구체적인 내용은 2025년 후반에 발표될 예정입니다.
기준일 현재 모든 주주 및 주식 관련 증권 보유자는 Alyea 배당에 참여할 자격이 있습니다. 현재로서는 주주 투표가 요구되지 않으나, 배당에 투표가 필요할 경우 회사가 이해관계자에게 통지할 것입니다.
ALT5 Sigma Corporation (NASDAQ:ALTS) a annoncé le 2 juin 2025 comme date de référence pour la séparation prévue des actifs de santé sous Alyea Therapeutics Corporation. La société vise à scinder ses segments santé et fintech afin que chaque entité puisse se concentrer sur ses besoins commerciaux respectifs. Les détails spécifiques de la transaction, qu'elle soit structurée en scission partielle, spin-off ou autre opération similaire, seront communiqués plus tard en 2025.
Tous les détenteurs d'actions et de titres sous-jacents aux actions à la date de référence seront éligibles à participer à la distribution Alyea. Actuellement, aucun vote des actionnaires n'est requis, mais la société informera les parties prenantes si un vote devient nécessaire pour la distribution.
ALT5 Sigma Corporation (NASDAQ:ALTS) hat den 2. Juni 2025 als Stichtag für die geplante Abspaltung der Gesundheitsvermögenswerte unter Alyea Therapeutics Corporation bekanntgegeben. Das Unternehmen beabsichtigt, seine Gesundheits- und Fintech-Segmente zu trennen, damit sich jede Einheit auf ihre jeweiligen Geschäftsbedürfnisse konzentrieren kann. Die genauen Details der Transaktion, ob als Split-off, Spin-off oder eine andere verwandte Transaktion, werden im Laufe des Jahres 2025 bekannt gegeben.
Alle Aktionäre und Inhaber von aktienbezogenen Wertpapieren zum Stichtag sind berechtigt, an der Alyea-Ausschüttung teilzunehmen. Derzeit ist keine Aktionärsabstimmung erforderlich, doch wird das Unternehmen die Beteiligten informieren, falls eine Abstimmung für die Ausschüttung notwendig wird.
- Strategic separation of healthcare and fintech segments allows for better business focus
- All equity holders will be eligible to participate in the Alyea distribution
- No shareholder vote requirement simplifies the process
- Lack of clarity on the final transaction structure (split-off vs. spin-off)
- Uncertainty about the timing and details of the distribution
- Potential for complex tax implications depending on the transaction structure
LAS VEGAS, NEVADA / ACCESS Newswire / May 21, 2025 / ALT5 Sigma Corporation (the "Company" or "ALT5") (NASDAQ:ALTS)(FRA:5AR1), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, today announces June 2, 2025 as the record date for the previously announced transaction involving further steps in the Company's formal separation of its healthcare assets, known as Alyea Therapeutics Corporation ("Alyea"). As previously announced, the Company has decided to separate its healthcare and fintech segments to allow each entity to concentrate on its unique business needs.
The Company expects that it will announce the scope and method of a partial or full disposition of its interests in Alyea, whether as a split-off or a spin-off or another related transaction, later this year, but wanted to provide its stakeholders and the market with a specific record date for such transaction. All record and beneficial holders of equity in the Company and all holders of equity underlying various securities of the Company on the record date, where applicable, will be able to participate in the distribution of Alyea in a transaction, the details of which are yet to be announced. No vote of the equity holders of the Company is required as of the date of this press release or as of the record date. The Company will advise its stakeholders and the market if a vote of the "record date security holders" of the Company will be required in connection with an Alyea distribution.
About ALT5 Sigma Corporation
ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1) is a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing settlement, payment and safe keeping of digital assets. The Company is one of the constituents of the Russell Microcap Index, as of June 28, 2024.
Founded in 2018, ALT5 Sigma, Inc. (a wholly owned subsidiary of ALT5 Sigma Corporation), provides next-generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT5 Sigma, Inc., through its subsidiaries, offers two main platforms to its customers: "ALT5 Pay" and "ALT5 Prime." ALT5 Sigma has processed over
ALT5 Pay is an award-winning cryptocurrency payment gateway that enables registered and approved global merchants to accept and make cryptocurrency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay's checkout widgets and APIs. Merchants have the option to convert to fiat currency(s) automatically or to receive their payment in digital assets.
ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access mobile phone application named "ALT5 Pro" that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime's FIX API, as well as through Broadridge Financial Solutions' NYFIX gateway for approved customers.
The Company is working on the separation of our biotech business that will move forward under "Alyea Therapeutics Corporation." Through its biotech activities, the Company is focused on bringing to market drugs with non-addictive pain-relieving properties to treat conditions that cause chronic or severe pain. Our patented product, a novel formulation of low-dose naltrexone (JAN123), is being initially developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs. The FDA has granted Jan123 Orphan Drug Designation for treatment of CRPS.
About Alyea Therapeutics Corporation
Alyea, an ALT5 company, is developing innovative, actionable solutions intended to help end the opioid crisis. Alyea is dedicated to funding resources toward innovation, technology, and education to find a key resolution to the national opioid epidemic, which is one of the deadliest and most widespread in the nation's history. Its drugs in the clinical trial pipeline have shown promise for their innovative targeting of the causes of pain as a strategic option for physicians averse to exposing patients to addictive opioids.
Forward-Looking Statements
This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the profitability and prospective growth of ALT5's platforms and business, that may include, but are not limited to, international currency risks, third-party or customer credit risks, liability claims stemming from ALT5's services, and technology challenges for future growth or expansion. This press release also contains general statements relating to risks that JAN 101 will treat PAD, that JAN 123 will treat CRPS, the timing of the commencement of clinical trials, that the FDA will permit approval through a 505(b)(2) pathway for JAN 123, that upon approval JAN 101 will immediately disrupt the PAD market, and other statements, including words such as "continue", "expect", "intend", "will", "hope", "should", "would", "may", "potential", and other similar expressions. Such statements reflect the Company's current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political, and social uncertainties, and contingencies. This press release also contains statements that are forward-looking in respect of the expected future partial or full disposition of the Company's interests in Alyea without specific=ty of the scope or methods thereof.
Many factors could cause the Company's actual results, performance, or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others, those detailed in the Company's periodic reports filed with the Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in the Company's filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. The Company cannot assure that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
Media Contact Investor Relations
IR@alt5sigma.com
1-800-400-2247
SOURCE: ALT5 Sigma Corp
View the original press release on ACCESS Newswire
FAQ
What is the record date for ALT5 Sigma's Alyea Therapeutics separation?
Will ALTS shareholders need to vote on the Alyea Therapeutics separation?
Who is eligible to participate in the ALTS Alyea distribution?
What type of separation is planned for Alyea Therapeutics from ALTS?
Why is ALT5 Sigma separating Alyea Therapeutics?
